HYK华因康品牌怎么样 申请店铺

我要投票 HYK华因康在基因检测行业中的票数:534 更新时间:2025-12-29
HYK华因康是哪个国家的品牌?「HYK华因康」是 深圳华因康基因科技有限公司 旗下著名品牌。该品牌发源于广东,由创始人盛司在2008-01-23期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力HYK华因康品牌出海!将品牌入驻外推网,定制HYK华因康品牌推广信息,可以显著提高HYK华因康产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

HYK华因康怎么样

华因康集团秉承“专业、严谨、创新、服务”的理念,自2008年创立以来,一直致力于中华民族健康事业,发展迅猛。迄今拥有深圳市华因康高通量生物技术研究院、深圳华因康基因科技有限公司、华因康基因检测中心及全国各地多家分支机构,成为以基因技术为核心,拥有雄厚研发支撑、具备研发、生产和应用三位一体的完整产业链的生物技术高科技集团。

研发中心–深圳市华因康高通量生物技术研究院拥有一支在机械、光学、电子、生化、软件、生物信息、生物医疗等技术领域具备尖端技术成果的科学家、教授、博士、博士后及行业专家组成的精英技术团队。研究院面向世界科学前沿和国家战略发展需求,以新型DNA测序分析技术的突破为契机,旨在研究高通量生物技术,开发高通量实验和检测设备,寻找高通量检测新方法,为我国生命科技领域的上游进行产业布局,搭建与基因技术相关的生命科技产业基础性研究平台,进行国际前沿基因组科学基础及应用研究与技术开发,提升我国基因技术自主创新能力。

产品中心-深圳华因康基因科技有限公司专业生产、销售高通量基因测序设备、生物试剂和基因信息分析软件,提供科研技术服务与生物信息数据分析技术服务。公司主导产品PSTAR高通量基因测序系统,填补了我国在生命科技产业核心装备、基因测序设备制造、试剂生产与生物信息分析服务等领域的空白,广泛应用于生命科学基础研究、临床诊断与治疗、疾病预防与保健以及新药研制等领域。

基因检测中心-华因康基因检测中心依托于华因康基因新一代高通量基因测序系统平台技术,是转化医学的专业化服务机构。中心以新一代高通量基因测序系统技术平台为核心,辅以实时荧光PCR平台、STR分析平台、免疫组化、荧光原位杂交等技术平台,覆盖了DNA、RNA、蛋白水平,测序、PCR、蛋白免疫组化、FISH等多种检测技术。已率先研发出多种适用于亚洲人的临床基因检测项目,专业提供“肿瘤个体化用药指导靶基因检测”临床技术服务,同时为临床提供疾病早期筛查、重大疾病分子标志物检测及与保健、优生优育相关的检测服务。与国内顶级医院及科研机构携手,开拓高通量基因测序技术在生命科学与医疗健康领域中的广阔应用,为人类的健康事业提供专业、贴心的个性化服务。

华因康基因(集团)将始终坚持“探索基因信息,提高生命价值”的宗旨,致力于打造基因生命科技在研发、应用、临床转化系统平台技术上的核心竞争力,彰显中国基因产业在世界竞争中的领航者地位,引领中国健康产业发展新方向。


Huayinkang group adheres to the concept of "professional, rigorous, innovative and service". Since its establishment in 2008, it has been committed to the cause of health of the Chinese nation, with rapid development. So far, it has Shenzhen huayinkang high throughput Biotechnology Research Institute, Shenzhen huayinkang Gene Technology Co., Ltd., huayinkang gene testing center and many branches all over the country. It has become a biotechnology high-tech group with gene technology as the core, strong R & D support, and a complete industrial chain of R & D, production and application. R & D Center - Shenzhen huayinkang high throughput Biotechnology Research Institute has an elite technical team composed of scientists, professors, doctors, postdoctors and industry experts with cutting-edge technical achievements in the fields of machinery, optics, electronics, biochemistry, software, biological information, biomedicine and other technical fields. Facing the needs of the world's scientific frontier and national strategic development, and taking the breakthrough of new DNA sequencing analysis technology as an opportunity, the research institute aims to study high-throughput biotechnology, develop high-throughput experiment and detection equipment, find new high-throughput detection methods, make industrial layout for the upstream of China's life science and technology field, and build a basic research platform of life science and technology industry related to gene technology To carry out basic and applied research and technological development of international frontier genomic science and improve the independent innovation ability of China's gene technology. Product Center - Shenzhen huayinkang Gene Technology Co., Ltd. specializes in the production and sales of high-throughput gene sequencing equipment, biological reagents and gene information analysis software, providing scientific research and technical services and biological information data analysis technical services. The company's leading product, pstar high-throughput gene sequencing system, has filled in the gaps in the core equipment of life science and technology industry, gene sequencing equipment manufacturing, reagent production and bio information analysis services in China, and is widely used in basic research of life science, clinical diagnosis and treatment, disease prevention and health care, and new drug development and other fields. Based on the platform technology of new generation high-throughput gene sequencing system of huayinkang gene, huayinkang gene testing center is a professional transformation medicine service organization. The center takes the new generation high-throughput gene sequencing system technology platform as the core, supplemented by real-time fluorescent PCR platform, STR analysis platform, immunohistochemistry, fluorescence in situ hybridization and other technology platforms, covering DNA, RNA, protein level, sequencing, PCR, protein immunohistochemistry, fish and other detection technologies. It has taken the lead in developing a variety of clinical gene detection projects suitable for Asians, providing professional clinical technical services of "tumor individualized drug use guidance target gene detection", and providing early disease screening, detection of major disease molecular markers and detection services related to health care, eugenics and eugenics. Together with the top domestic hospitals and scientific research institutions, we will explore the wide application of high-throughput gene sequencing technology in the field of life science and medical health, and provide professional and intimate personalized services for human health. Huayinkang gene (Group) will always adhere to the tenet of "exploring gene information and improving life value", devote itself to building the core competitiveness of gene life technology in research and development, application and clinical transformation system platform technology, highlight the leading position of China's gene industry in the world competition, and lead the new development direction of China's health industry.

本文链接: https://brand.waitui.com/4c1ad289a.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

汇率没有单边走势,双向波动是常态

本轮人民币汇率的走强可追溯至今年10月中旬,截至目前,人民币对美元汇率升值幅度接近1.7%。一些观点认为,近期人民币汇率走强主要受美联储降息带动美元指数走弱,以及岁末结汇需求不断释放等内外部因素影响。不过,这些更多属于推动人民币阶段性升值的短期、季节性扰动因素,不能简单线性推导认为人民币就此进入持续单边升值通道,人民币汇率走势仍存在较大不确定性。(证券时报)

52分钟前

中信建投:A股跨年行情已经启动

36氪获悉,中信建投证券最新研报指出,经历了此前中期调整的完成,近期上证指数八连阳传递了积极信号,中信建投认为A股跨年行情已经启动。在机构投资者的一致乐观预期下,明年春季躁动行情有望提前;海外AI模型调整结束,美国战略重心西迁,海外流动性和风险持续改善;近期十五五产业政策与事件密集发布,投资者政策预期高涨;以上三大预期共同推动市场跨年行情启动。

52分钟前

创新药投资已至岔路口,基金经理热议融资潮

9月以来,创新药板块持续调整。港股创新药相关指数跌幅已超过20%,部分未盈利的公司跌幅尤为突出,已跌超40%。在市场习惯了创新药商业拓展(BD)交易的宏大叙事后,投资者的情绪阈值明显提升,与之相伴的是前期大量涌入的资金开始退出。此外,今年以来,港股创新药企业IPO数量及融资额大增,市场人士对此颇有争议。在业内人士看来,创新药行业长期的贝塔逻辑不变,但定价的重心需要回归企业本身。(中证网)

52分钟前

一汽股权溢价认购零跑汽车近7500万股

36氪获悉,零跑汽车公告,12月28日,公司与一汽股权订立内资股认购协议,据此,公司已有条件同意向一汽股权发行74,832,245股内资股,认购价为每股内资股认购股份人民币50.03元(相当于55.29元港元,零跑最新收盘价为49.94港元)。内资股认购股份将根据一般授权发行。

52分钟前

并购潮遇上涨价潮,锂电隔膜行业供需有望趋于平衡

在行业加速整合的背后,多家隔膜厂商启动涨价,行业景气度持续升温。多数受访人士认为,当前下游市场需求持续增长,而隔膜行业扩产动力不足,未来供需面有望逐步改善,并带动产品价格回升、企业盈利修复。在“反内卷”背景下,隔膜行业的竞争焦点已从规模扩张转向结构升级,具备超薄高强隔膜研发量产能力,且拥有全球化交付能力的企业,将凭借差异化竞争优势,在行业洗牌中抢占先机。(证券时报)

52分钟前

本页详细列出关于HYK华因康的品牌信息,含品牌所属公司介绍,HYK华因康所处行业的品牌地位及优势。
咨询